X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025 ...

X4 Pharmaceuticals BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today ...

X4 Pharmaceuticals (XFOR) said it will conduct a one-for-thirty reverse stock split of the company’s common stock.

BOSTON - X4 Pharmaceuticals (NASDAQ:XFOR), a biopharmaceutical company focusing on rare immune diseases, will implement a one-for-thirty reverse stock split of its common stock, the firm announced ...

BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective ...

X4 Pharmaceuticals (XFOR) announced that its board of directors has determined to effect a one-for-thirty reverse stock split of the company’s ...

Insta360’s X5 arrives with some compelling spec upgrades that don’t just prove its worth against the Insta360 X4, they rather show up the GoPro 360 Max — at least on paper. There are three ...

BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that its board of ...

BOSTON - X4 Pharmaceuticals (NASDAQ:XFOR), a biopharmaceutical company focusing on rare immune diseases, will implement a one-for-thirty reverse stock split of its common stock, the firm announced ...

Here's how you can use Napkin AI to create charts and graphs from your data. Sign up to get the BEST of Tom's Guide direct to your inbox. Get instant access to breaking news, the hottest reviews ...

EDT X4 Pharmaceuticals (XFOR) trading halted, news pendingStay Ahead of the Market: Discover outperforming stocks and invest smarter ...

Patients in the US with the ultra-rare disease WHIM syndrome now have their first approved treatment, after X4 Pharma’s Xolremdi was given a green light by the FDA. Oral CXCR4 antagonist ...